β-Caryophyllene [87-44-5]
Referência HY-N1415-500mg
Tamanho : 500mg
Marca : MedChemExpress
| Description |
β-Caryophyllene is a CB2 receptor agonist. |
||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IC50 & Target |
|
||||||||||||||||||||
| Cellular Effect |
|
||||||||||||||||||||
| In Vitro |
Among the tested cancer cells, β-Caryophyllene demonstrates selective anti-proliferative effect against three cancer cell lines, namely HCT 116 (colon cancer, IC50=19 μM), PANC-1 (pancreatic cancer, IC50=27 μM), and HT29 (colon cancer, IC50=63 μM) cells, whereas β-Caryophyllene exhibits either moderate or poor cytotoxic effects against ME-180, PC3, K562 and MCF-7. Results show that β-Caryophyllene possesses higher selectivity towards the colorectal cancer cells (HCT 116), with selectivity index (SI)=27.9, followed by PANC-1 and HT 29 cells with SI=19.6 and 8, respectively. The apoptotic index estimated for β-Caryophyllene treatment on HCT 116 cells after 24 h treatment is 64±0.04. β-Caryophyllene at 10 μM concentration, causes significant nuclei condensation after 6 h of treatment. β-caryophyllene exhibits a dose and time-dependent inhibitory effect on the motility of HCT 116 cells[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||||||
| In Vivo |
Treatment with β-Caryophyllene at different doses does not show any effects on swimming speed during the test. Oral treatment with β-Caryophyllene ameliorates the rise in β-amyloid deposition in the transgenic mice in a roughly dose-dependent manner, and the two higher doses exhibit almost equal effects in modifying the β-amyloid burden. The number of activated astroglial cells is higher in vehicle-treated mouse brains than in β-Caryophyllene-treated mouse brains with different doses. β-Caryophyllene is effective at reducing the enhancement of the COX-2 protein level found in vehicle-treated APP/PS1 mice[1]. Animals treated with β-Caryophyllene display higher values of object recognition index than their vehicle-treated counterparts [t(14)=4.204, P<0.05]. The total time spent in object exploration during the test trial is not significantly different between β-Caryophyllene-treated and vehicle-treated animals (t(14)=0.5874, P>0.05). Treatment with β-Caryophyllene does not significantly alter these seizure-induced neurochemical changes[3]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||||||
| Essai clinique |
|
||||||||||||||||||||
| Masse moléculaire |
204.35 |
||||||||||||||||||||
| Formule |
C15H24 |
||||||||||||||||||||
| CAS No. | |||||||||||||||||||||
| Appearance |
Liquid (Density: 0.902 g/cm3) |
||||||||||||||||||||
| Color |
Colorless to light yellow |
||||||||||||||||||||
| SMILES |
C=C1CC/C=C(C)/CC[C@@]2(02)C(C)(C)C[C@]1202 |
||||||||||||||||||||
| Structure Classification | |||||||||||||||||||||
| Initial Source | |||||||||||||||||||||
| Livraison | Room temperature in continental US; may vary elsewhere. |
||||||||||||||||||||
| Stockage |
|
||||||||||||||||||||
| Solvant et solubilité |
In Vitro:
Ethanol : ≥ 176.67 mg/mL (864.55 mM) DMSO : 25 mg/mL (122.34 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) H2O : < 0.1 mg/mL (insoluble) *"≥" means soluble, but saturation unknown. Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
For the following dissolution methods, please prepare the working solution directly.
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
|
||||||||||||||||||||
| Pureté et documentation | |||||||||||||||||||||
| Références |
|

